Related by context. All words. (Click for frequent words.) 78 CYT# potent vascular disrupting 77 cisplatin gemcitabine 77 relapsed MM 75 thalidomide Thalomid 75 lymphomas leukemias 75 erlotinib Tarceva ® 74 xenograft models 74 novel VDA molecule 74 evaluating tivozanib 74 PI3K/Akt pathway inhibitor 74 FUSILEV enhances 74 fosbretabulin 74 vinca alkaloid 74 receptor tyrosine kinase inhibitor 74 orally administered inhibitor 74 Darinaparsin 74 mitoxantrone plus 73 Omacetaxine 73 papillary renal cell carcinoma 73 Bezielle 73 recurrent glioblastoma multiforme 73 MAGE A3 ASCI 73 Platinol ® cisplatin 73 estramustine 73 AAG geldanamycin analog 73 AKT inhibitor 73 cisplatin resistant 73 IMiDs ® 73 kidney urologic 73 unresectable tumors 73 Aplidin 72 oral picoplatin 72 Hsp# Inhibitor 72 lenalidomide Revlimid R 72 leukemia AML 72 essential thrombocythemia ET 72 Archexin 72 LHRH receptor positive 72 selective modulator 72 oral prodrug 72 CTAP# Capsules 72 trastuzumab Herceptin ® 72 metastatic gastric 72 ® lenalidomide 72 2 methoxyestradiol 72 GVAX ® 72 receptor inhibitor 72 HGS ETR1 mapatumumab 72 antiproliferative effects 72 taxane resistant 72 trastuzumab Herceptin R 72 preclinical efficacy 72 humanised monoclonal antibody 72 sorafenib Nexavar 72 Xanafide 72 Gleevec resistant 72 TRAIL R2 72 Tarceva TM 72 pegylated liposomal doxorubicin 72 irinotecan doxorubicin oxaliplatin paclitaxel 72 paclitaxel poliglumex 72 adriamycin 72 PROSTVAC VF 72 mouse xenograft models 72 Temsirolimus 72 K ras mutations 71 steroid refractory 71 galiximab 71 ENMD # 71 paclitaxel cisplatin 71 antimitotic 71 TRAIL R1 71 refractory chronic lymphocytic 71 imatinib Gleevec ® 71 liposomal formulation 71 docetaxel Taxotere ® 71 Doxil ® 71 OMP #M# 71 LymphoStat B TM 71 MGd 71 metastatic pancreatic 71 pancreatic prostate 71 lenalidomide dexamethasone 71 histone deacetylase inhibitor 71 HMG CoA reductase inhibitors 71 Teriflunomide 71 FOLFOX6 chemotherapy regimen 71 alkylating agent 71 metaglidasen 71 Ribavirin causes 71 Pharmacokinetics PK 71 R Saizen R 71 alkylating 71 hA# 71 5 FU leucovorin 71 SPRYCEL ® 71 Aflibercept 71 Vidaza ® 71 alvespimycin 71 Lenocta 71 tumor xenograft models 71 haematologic 71 5 fluorouracil leucovorin 71 GW# [003] 71 Phase 1b clinical trials 71 proteasome inhibitor 71 nucleoside analog 71 pathophysiological effects 71 sarcoma melanoma 71 novel emulsion formulation 71 cMET 71 VEGFR2 inhibitor 71 non nucleoside inhibitor 71 alfa 2a 71 induced tumor regression 71 hypereosinophilic syndrome 70 gemcitabine Gemzar ® 70 LymphoStat B belimumab 70 Squalamine 70 Panzem R 70 dasatinib Sprycel ® 70 gefitinib Iressa 70 lintuzumab SGN 70 MKC# MT 70 non resectable 70 Flu Cy 70 Nilotinib 70 refractory acute myeloid 70 Dapagliflozin 70 dacarbazine DTIC 70 paclitaxel Taxol ® 70 YONDELIS 70 Panzem R NCD 70 ara C 70 TNF Tumor Necrosis Factor 70 humanized therapeutic 70 Triapine R 70 Hormone Refractory Prostate Cancer 70 bortezomib Velcade 70 lymphoid malignancies 70 pan HDAC inhibitor 70 PSMA ADC 70 Certolizumab pegol 70 ZACTIMA 70 monoclonal antibody conjugated 70 HGS ETR2 70 PKC# 70 XL# inhibits 70 radiolabeled TM# 70 VEGF inhibitors 70 tumors GIST 70 p# MAP kinase inhibitor 70 ritonavir boosted 70 Afatinib 70 Bayer HealthCare Onyx Pharmaceuticals 70 selective kinase inhibitor 70 Fludara ® 70 Orally administered 70 Amgen Neulasta R 70 Onconase 70 Ph + acute lymphoblastic 70 multitargeted 70 riociguat 70 refractory colorectal cancer 70 anthracycline taxane 70 Anthracycline 70 AML MDS 70 acyclovir Lauriad R 70 Taxotere chemotherapy 70 TransVax ™ 70 immuno modulatory 70 Virulizin ® 70 NS5B polymerase 70 triggers apoptosis programmed 70 Aurora Kinase 70 fallopian tube cancers 70 gemcitabine Gemzar 70 HIV HCV coinfected 70 antiangiogenic therapy 70 androgen receptor antagonist 70 indolent follicular non 70 antisense inhibitors 70 T1c 70 Antitumor Activity 70 Cloretazine 70 docetaxel chemotherapy 70 Diffuse Large B 70 PEG SN# 70 accumulate preferentially 70 myelodysplastic myeloproliferative diseases 70 itraconazole Sporanox 70 somatostatin analog 70 dasatinib Sprycel 69 TRIOLEX HE# APOPTONE HE# 69 murine model 69 prostate carcinoma 69 Quinamed 69 Seliciclib 69 Romidepsin 69 Mg Uk 69 Solazed TM 69 efaproxiral 69 Bosutinib 69 lymphoid tumors 69 antiretroviral naïve 69 OHR/AVR# 69 TO AVOID PREGNANCY WHILE 69 ovarian carcinoma 69 stage IIIb IV 69 Safinamide 69 immune modulating 69 cyclophilin inhibitors 69 metastatic colorectal 69 refractory metastatic 69 huN# DM1 69 EGFR HER2 69 sunitinib Sutent ® 69 PEGylated anti 69 mapatumumab 69 OMNARIS HFA 69 Zalypsis 69 hypercholesterolemic patients 69 DCVax R 69 XL# anticancer compounds 69 potent antitumor activity 69 metastatic neuroendocrine tumors 69 forodesine 69 weekly subcutaneous injections 69 R sorafenib tablets 69 Combination REOLYSIN R 69 Phase #b/#a clinical 69 Telintra 69 pharmacokinetic PK study 69 rituximab refractory 69 Completes Patient Enrollment 69 pancreatic colon 69 Letairis ambrisentan 69 topoisomerase II inhibitor 69 Albuferon TM 69 5 Fluorouracil 69 Meets Primary Endpoint 69 ALB # 69 mTOR mammalian target 69 myeloablative 69 vinca alkaloids 69 Deforolimus 69 5alpha reductase 69 R lenalidomide 69 Annamycin 69 null responder 69 plus prednisone prednisolone 69 5 HT2A serotonin 69 Phase 2b Clinical Trial 69 GMX# 69 biliary tract cancer 69 evaluating mipomersen 69 ATRA IV 69 paclitaxel Taxol 69 Pathway Inhibitor 69 bladder ovarian 69 recurrent metastatic 69 candidates Azedra TM 69 Vidofludimus 69 orally inhaled migraine 69 adjuvant cisplatin 69 BEXXAR Therapeutic Regimen 69 docetaxel Taxotere 69 CRLX# 69 Presents Preclinical Data 69 including eniluracil ADH 69 heavily pretreated 69 oral rivaroxaban 69 Thiarabine 69 mertansine 69 oral clodronate 69 pretransplant 69 radiation sensitizer 69 undergoing hematopoietic stem 69 mGluR2 NAM 69 immunomodulatory properties 69 Interferon alpha 69 Interferon Beta 69 tramiprosate Alzhemed TM 69 Kinoid 69 skeletal metastases 69 Ophena TM 69 interleukin IL -# 69 mTOR inhibition 69 motesanib diphosphate 69 pain palliation 69 ® bortezomib 69 Evoltra ® 69 hereditary emphysema 69 small molecule tyrosine 69 interferon IFN 69 nonmetastatic 69 Azacitidine 69 MEK inhibitors 69 inecalcitol 69 Kahalalide F 69 CML CP 69 refractory NSCLC 69 achieved CCyR 69 prokinetic agent 69 headache nasopharyngitis 69 Prolongs Survival 69 metastatic renal 69 imexon 69 gallium nitrate 69 cyclophosphamide doxorubicin vincristine 69 doxorubicin cyclophosphamide 69 basal cell carcinoma BCC 69 antibody MAb 69 Vidaza azacitidine 69 rhIGF-I/rhIGFBP-3 69 mda 7 69 antiangiogenesis therapies 69 cilengitide 68 radiotherapy RT 68 Xelox 68 multiple myeloma MM 68 Peginterferon alfa 2b 68 depsipeptide 68 zoledronate 68 beta 1a 68 neovasculature 68 factor TNF receptor 68 CG# [003] 68 IMPDH inhibitor 68 FOLFOX chemotherapy 68 Thiovir 68 Patients Treated With 68 liposomal amphotericin B 68 Fluorouracil 68 mGluR5 NAM 68 ocular formulation 68 relapsing remitting MS RRMS 68 Initiates Clinical Trial 68 relapsed leukemia 68 Sipuleucel T 68 LT NS# 68 sorafenib tablets 68 hormone refractory metastatic prostate 68 albiglutide 68 neratinib 68 Pegylated Interferon 68 adalimumab Humira 68 somatostatin 68 Tß4 68 JAK inhibitors 68 LAB CGRP 68 metastatic malignant 68 syngeneic 68 INSPIRE Trial Phase III 68 Interferon beta 68 Novel Oral 68 Temodar ® 68 busulfan 68 daily subcutaneous injections 68 Begins Dosing 68 liposomal doxorubicin 68 hyperphenylalaninemia HPA due 68 severe hypersensitivity reactions 68 ELACYT 68 Cardiotoxicity 68 BR.# 68 epithelial tumors 68 mg kg BID 68 favorable pharmacokinetic profile 68 myeloproliferative diseases 68 pancreatic islet cell 68 targeted antifolate 68 gemcitabine cisplatin 68 denileukin diftitox 68 CIMZIA TM 68 synthase TS 68 Epothilone D 68 MGN# 68 novel histone deacetylase 68 uricase 68 CYP#D# inhibitor 68 TNF alpha selectively neutralizing 68 CLL SLL 68 colorectal carcinoma 68 follicular Non Hodgkin 68 potentially hepatotoxic 68 systemically administered 68 nucleotide analogs 68 Muraglitazar 68 Initiates Phase II 68 angiotensin analog 68 finasteride Proscar 68 anthracyclines taxanes 68 tryptase 68 TTR amyloidosis 68 Elotuzumab 68 Xeloda ® 68 ZOLINZA 68 interferon gamma 1b 68 tumorigenicity 68 HDL Selective Delipidation 68 anti angiogenic agents 68 Soft Tissue Sarcoma 68 huC# DM4 68 MCSP respectively 68 metastatic castration resistant 68 chimeric monoclonal antibody 68 Irinotecan 68 Enzastaurin 68 HCV protease inhibitors 68 potent suppressor 68 pharmacodynamic profiles 68 Achieves Primary Endpoint 68 aspirin clopidogrel 68 systemic anaplastic large 68 recurrent metastatic ovarian cancer 68 nucleotide analog 68 cediranib 68 neovascular diseases 68 inhibit platelet function 68 Campath alemtuzumab 68 hypoxia activated prodrug 68 vapreotide acetate 68 KRAS mutant 68 sunitinib Sutent 68 leukemia multiple myeloma 68 TÎ ² 4 68 Fulvestrant 68 ACTEMRA TM 68 CIMZIA TM certolizumab pegol 68 alefacept 68 Factor Receptor 68 potently inhibit 68 imatinib Gleevec 68 Alfacell proprietary ribonuclease 68 Hodgkin lymphoma HL 68 pharmacodynamic PD 68 investigational monoclonal antibody 68 virus HCV protease inhibitor 68 nilotinib Tasigna ® 68 CIMZIA ™ 68 antisense inhibition 68 Epratuzumab 68 melphalan prednisone 68 small molecule Hedgehog 68 intravascular hemolysis 68 immunomodulation 68 taxane chemotherapy 68 lenalidomide Revlimid 68 recurrent epithelial ovarian 68 Tarvacin Anti Cancer 68 paclitaxel Taxol R 68 Tyrosine Kinase Inhibitor 68 gemcitabine carboplatin 68 Alequel 68 fibrosarcoma 68 PD LID 68 R roscovitine 68 mTOR inhibitors 68 castrate resistant prostate cancer 68 Cytarabine 68 radezolid 68 IMiDs R 68 telomerase therapeutic 68 Tanespimycin 68 compound AEZS 68 advanced metastatic renal 68 phase III isavuconazole 68 polycythemia vera PV 68 recurrent NSCLC 68 Hepatotoxicity 68 generation purine nucleoside 68 myelofibrosis polycythemia vera 68 colon carcinoma 68 systemic juvenile idiopathic 68 chronic eosinophilic leukemia 68 CIMZIA R 68 Amgen Neulasta ® 68 cetuximab Erbitux R 68 Presents Preclinical 68 Vicinium TM 68 ospemifene 68 untreated metastatic colorectal 68 sorafenib Nexavar ® 68 SYN# 68 mutated K ras 68 cutaneous T 68 Apoptone 68 pharmacokinetic characteristics 68 hyaluronidase enzyme 68 HER2 positive metastatic breast 68 taxane refractory 68 IMiDs ® compound 68 Fingolimod 68 Elacytarabine 68 targeted radiotherapeutic 68 UPLYSO 68 SSc 68 Tolvaptan 68 gamma secretase inhibitor 68 anti amnesic 68 chemotherapy cisplatin 68 targeting CD# 68 non resectable metastatic 68 epoetin alpha 68 cyclophosphamide methotrexate 68 JAK2 inhibitor 68 TRAIL induced apoptosis 68 Pegylated 68 oral JAK1 68 PPAR gamma agonist 68 opioid naive 68 refractory indolent non 68 potent inducer 68 REMINYL ® 68 Newly Diagnosed Multiple Myeloma 68 allogeneic HSCT 67 evaluating satraplatin 67 Prodarsan R 67 acetonide FA 67 neutropenia dehydration dyspnea 67 erythropoietic 67 untreated metastatic melanoma 67 paricalcitol 67 NS#/#A protease 67 targets EpCAM expressing 67 metastatic GIST 67 gastric adenocarcinoma 67 novel nucleoside analog 67 TTF Therapy 67 induced mucositis 67 Canvaxin TM 67 administered intranasally 67 Cutaneous T 67 amrubicin 67 pharmacologically active isomer 67 doxorubicin Adriamycin 67 Pemetrexed 67 Zemplar Capsules 67 inhibits VEGF 67 TLR7 agonist 67 PEGylated interferon 67 CYP#A# CYP#D# 67 ovarian endometrial 67 antitumor efficacy 67 milatuzumab 67 docetaxel Taxotere R 67 ANAVEX #-# [001] 67 torsemide ER 67 preclinical xenograft models 67 injectable investigational 67 GVAX R 67 visilizumab 67 Pruvel TM 67 CHOP chemotherapy 67 HCV NS5B polymerase 67 antiangiogenic agent 67 substantially excreted 67 elotuzumab 67 Darusentan 67 antitumor effects 67 thetreatment 67 CCR9 antagonist 67 radiochemotherapy 67 trial evaluating PRX# 67 gastrointestinal stromal tumors GISTs 67 cyclin dependent kinase inhibitor 67 Sapacitabine 67 Ceplene/IL-2 67 extensively metabolized 67 Cerebril TM 67 Initiates Enrollment 67 novel therapeutic antibodies 67 Neulasta ® 67 protein tyrosine phosphatase 1B 67 Myelodysplastic Syndrome MDS 67 bevacizumab Avastin ® 67 maximally tolerated lipid lowering 67 RRM1 67 phase IIb III 67 advanced medullary thyroid 67 hepatoma 67 non nucleoside HCV 67 bronchodilatory 67 Obatoclax 67 HGS# 67 pancreatic lung 67 nonnucleoside reverse transcriptase inhibitors 67 Reports Preclinical Data 67 Imatinib mesylate 67 cytokine refractory 67 vinorelbine tartrate 67 receiving XGEVA 67 PEGylated Fab fragment 67 Granulocyte Colony Stimulating Factor 67 BRAF inhibitor 67 TELINTRA 67 LBH# 67 targeted nucleotide prodrug 67 vidofludimus 67 develop HBV reactivation 67 oncolytic virus therapies 67 HepG2 cells 67 formerly LymphoStat B 67 untreated metastatic pancreatic 67 OMP #R# 67 IMA# 67 Forodesine HCl 67 EDEMA3 trial 67 concurrent chemoradiation 67 chronic myeloid 67 oral isoform selective HDAC 67 BCG refractory carcinoma 67 selective agonist 67 Proellex TM 67 Zybrestat 67 MVA MUC1 IL2 67 pediatric acute lymphoblastic 67 Mycophenolate Mofetil 67 oral nucleoside analogue 67 oral beclomethasone dipropionate 67 antiangiogenic activity 67 Personalized Immunotherapy 67 biologic DMARD 67 idarubicin 67 Cloretazine R 67 colorectal adenoma 67 generation Hsp# inhibitor 67 cancer mCRC 67 Akt inhibitor 67 receiving VELCADE 67 MTP inhibitor 67 immunomodulatory agents 67 Aeolus Pharmaceuticals Announces 67 EDARBI 67 bortezomib Velcade R 67 Adjuvant Treatment 67 vaccine RiVax TM 67 intranasal formulation 67 highly selective inhibitor 67 Curaxin CBLC# 67 nucleotide analogue 67 Refractory Hodgkin Lymphoma 67 taxane therapy 67 interferon beta 1a infertility 67 oxaliplatin Eloxatin 67 sulindac 67 Symadex 67 AEGR 67 oblimersen 67 dexamethasone Decadron 67 Relapsed Refractory 67 Decitabine 67 tamoxifen Nolvadex ® 67 liposome encapsulated 67 Kamada AAT 67 antiangiogenesis 67 PRTX 67 Cimzia TM 67 endothelin receptor 67 iobenguane 67 Angiotensin Converting Enzyme 67 androgen independent 67 teriflunomide 67 Thalomid ® 67 APOPTONE 67 Paraplatin ® carboplatin 67 anticancer activity 67 S/GSK# 67 hepatorenal syndrome 67 bevacizumab Avastin R 67 Recombinant Human 67 colorectal lung 67 Gemzar gemcitabine 67 infused intravenously 67 Preclinical Study 67 PNP inhibitor 67 histone deacetylase HDAC inhibitor 67 NMDA antagonists 67 Alkeran 67 next generation URAT1 67 pharmacokinetic interactions 67 included exfoliative dermatitis 67 lipid lowering therapies 67 aMCI precursor 67 autoantibody positive 67 Pivotal Phase III 67 XL# XL# 67 PhG alpha 1 67 selectively inhibited 67 prednisone prednisolone plus 67 colorectal gastric 67 Wellmune WGP 67 azilsartan medoxomil 67 Capecitabine 67 anti CD3 67 OncoVex 67 Genasense ® 67 human IgG1 monoclonal 67 previously untreated follicular 67 sapacitabine CYC# 67 platelet dysfunction 67 lexidronam injection 67 histologic subtype 67 SUTENT ® 67 Myelofibrosis 67 cisplatin chemotherapy 67 BZL# 67 Dasatinib 67 rituximab Rituxan 67 Initiate Clinical Trial 67 Exelixis compounds 67 Trastuzumab DM1 67 visceral metastases 67 products MKC# PP 67 CD8 + cytotoxic 67 fluvastatin 67 potently inhibited 67 sitaxsentan 67 basal bolus regimen 67 CYP#A# substrate 67 Bucindolol 67 pertuzumab 67 Vandetanib 67 p# alpha [001] 67 ThermoDox R 67 rheumatoid arthritis psoriatic arthritis 67 interferon alfa 2b 67 fluoropyrimidine 67 sarcomatoid 67 flavopiridol 67 ATC ovarian cancer 67 alfuzosin 67 circulating endothelial cells 67 trastuzumab DM1 T DM1 67 CDK cyclin dependent 67 bexarotene 67 colorectal adenocarcinoma 67 cis retinoic acid 67 cyclophosphamide chemotherapy 67 axitinib 67 #I TM# 67 endocrine therapies 67 EGFR tyrosine kinase inhibitors 67 Gemzar ® 67 DEB# 67 compound INCB# 67 ZFN modified 67 Vascugel 67 Heterozygous Familial Hypercholesterolemia 67 toenail onychomycosis 67 fusion enhancers 67 Zoraxel 67 selective inhibition 67 panitumumab Vectibix 67 rhITF 67 HER2 ErbB2 67 Initiate Phase 67 motesanib 67 pomalidomide 67 highly selective endothelin 67 VELCADE melphalan 67 microtubule inhibitor 67 OvaRex R 67 Amrubicin 67 irinotecan chemotherapy 67 HQK 67 SinuNase TM 66 TTR gene 66 pharmacokinetic equivalence 66 myopathy rhabdomyolysis 66 Cleviprex TM clevidipine 66 novel topoisomerase 66 recurrent glioblastoma multiforme GBM 66 redox active 66 advanced hepatocellular carcinoma 66 Shows Promise Against 66 administered subcutaneously 66 velafermin 66 elacytarabine 66 aripiprazole Abilify 66 irreversible inhibitor 66 Aplidin R 66 anti fibrotic 66 etanercept Enbrel 66 PrevOnco ™ 66 fallopian tube carcinoma 66 Cloretazine ® 66 HSP# inhibitor 66 GOUT 66 CINQUIL 66 agonistic human 66 surgical debulking 66 davunetide intranasal AL 66 Insulin detemir 66 topical gel formulation 66 Fludarabine 66 Vidaza R 66 acadesine 66 Genz # 66 colorectal liver metastases 66 adrenocortical cancer 66 maximally tolerated dose 66 Vitaxin 66 Erlotinib 66 sodium thiosulfate STS 66 methylnaltrexone bromide 66 recurrent malignant glioma 66 docetaxel Injection Concentrate 66 alpha interferons 66 histamine dihydrochloride 66 immunotherapeutic agent 66 locoregional recurrence 66 PEGylated interferon beta 1a 66 reversible inhibitor 66 interferon alpha IFN 66 mg administered orally 66 humanized interleukin 6 66 pregabalin Lyrica 66 Mg Usa 66 CDK inhibitor 66 Liprotamase 66 Kit CD# positive 66 volociximab 66 Pegylated interferon 66 relapsed ALL 66 Camptosar ® 66 Phase 1a clinical 66 adecatumumab MT# 66 Sudhir Agrawal D.Phil 66 Chronic Lymphocytic Leukemia CLL 66 invasive lobular 66 DITPA 66 Trial Evaluating 66 somatostatin analogue 66 selective orally bioavailable 66 HuMax 66 vascular disrupting agents 66 cell lymphoma CTCL 66 imatinib resistant 66 superficial bladder cancer 66 pyrimidine nucleoside analog 66 oral deforolimus 66 INCB# [003] 66 potency selectivity 66 progressive metastatic prostate 66 tigecycline 66 mRCC 66 TBC# 66 FOLFOX6 66 epirubicin cyclophosphamide 66 Tesmilifene 66 humanized monoclonal antibodies 66 tumor histology 66 ß blockers 66 Aptivus ® 66 AZT zidovudine Retrovir 66 omega interferon 66 ixabepilone 66 PEG IFN 66 chlorambucil 66 candidate CRLX# 66 INCB# [001] 66 effector function 66 daunorubicin 66 Nitazoxanide 66 liposome formulation 66 HBeAg positive patients 66 #mg ATC 66 Hedgehog Pathway Inhibitor 66 Sphingomab TM 66 primary hypercholesterolemia 66 Patients Receiving 66 YONDELIS R 66 DNA methyltransferase inhibitors 66 anastrazole 66 8mg/kg 66 RhuDex R 66 Budesonide foam crofelemer 66 RoACTEMRA 66 Squamous 66 Pafuramidine 66 BARACLUDE ® 66 EOquin TM phase 66 acute humoral rejection 66 alpha antagonist 66 kinase inhibition 66 oxidative stress inducer 66 unconjugated 66 Allovectin 7 ® 66 acute promyelocytic leukemia APL 66 Anti Tumor 66 Known hypersensitivity 66 deCODE ProstateCancer TM 66 ISTODAX ® 66 temozolomide TMZ 66 pancreatic adenocarcinoma 66 treatment naive genotype 66 EGFR mutation positive 66 Motesanib 66 pharmacodynamic properties 66 idiopathic thrombocytopenic purpura ITP 66 breast pancreatic 66 corticosteroid dexamethasone 66 pegylated alpha interferon 66 demonstrated clinically meaningful 66 GERD migraine headaches 66 porcine derived 66 radiation chemoradiation 66 humanised antibody 66 memantine Namenda 66 RhuDex TM 66 catheter occlusion 66 low dose cytarabine 66 ANAVEX #-# [002] 66 endothelin receptor antagonists 66 intratumoral injection 66 adefovir dipivoxil 66 Capesaris 66 taxane chemotherapy administered 66 SinuNase ™ 66 drug zotarolimus 66 Fluvastatin 66 azacytidine 66 postoperative chemotherapy 66 cannabinor 66 Neupogen ® 66 potent antiproliferative 66 evaluating REVLIMID 66 evaluating picoplatin 66 Pharmacodynamic 66 refractory gout 66 Naive Patients 66 prostanoid 66 oral antidiabetic medication 66 metastatic colorectal carcinoma 66 pegylated interferon alfa 2a 66 localized renal 66 gastro intestinal inflammation 66 cardiac repolarization 66 lapatinib Tykerb 66 prucalopride 66 IFN α 66 leukemia CLL 66 topically administered 66 completely resected 66 Adenoscan R 66 HER2 expression 66 inhibit metastasis 66 p# biomarker 66 SERMs 66 Anti VEGF 66 EGS# 66 arsenic trioxide injection 66 hMG 66 fluorouracil leucovorin 66 Panzem NCD 66 TransVax 66 5 HT6 receptor 66 abacavir Ziagen 66 CEQ# 66 ARRY # 66 hormone receptor negative 66 Parathyroid Hormone 66 histologies 66 topical gel containing 66 delafloxacin 66 ChronVac C R 66 neoadjuvant treatment 66 anthracycline containing 66 panobinostat 66 Glioblastoma Multiforme 66 lumiliximab 66 Paraplatin ® 66 investigational humanized monoclonal antibody 66 Danazol 66 Phase #/#a trial 66 immune modulator 66 soluble tumor necrosis 66 Luteinizing Hormone Releasing Hormone 66 metastatic bladder 66 novel tubulin binding 66 DCVax ® 66 humanized monoclonal 66 IL# PE#QQR 66 HIV coinfected 66 kilogram mg kg 66 clevidipine 66 pharmacogenomic translational research 66 multikinase inhibitor 66 unresectable HCC 66 brivanib 66 CTAP# 66 dimeglumine 66 polycythemia vera essential thrombocythemia 66 refractory AML 66 HER2 overexpression 66 abnormal p# 66 Romiplostim